Effect of Sodium-glucose Cotransporter 2 Inhibitors on Cardiac Function in Patients with Chronic Heart Failure Combined with Renal Insufficiency
Objective:To analyze the effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in patients with chronic heart failure (CHF) combined with renal insufficiency.Method:From January 2021 to December 2023,110 patients with CHF combined with renal insufficiency in Wuhu Second People's Hospital were selected as the study subjects.They were divided into control group (n=55) and study group (n=55) according to random number table method,and received conventional treatment or combined SGLT-2 inhibitor treatment,respectively.The clinical efficacy,serological indexes,cardiac function indexes and the incidence of adverse reactions were compared between the two groups.Result:The total effective rate of the study group was higher than that of the control group,the difference was statistically significant (P<0.05).Compared with those before treatment,galactoagglutinin-3 (Gal-3),soluble intercellular adhesion molecule-1 (sICAM-1),N-terminal pro-brain natriuretic peptide (NT-proBNP),serum cardiac ankyrin repeat protein (CARP) and serum mitochondrial coupling factor-6 (CF6) were decreased in both groups after treatment,those of the study group were lower than those of the control group (P<0.05).After treatment,the left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) of the study group were lower than those of the control group,and the left ventricular ejection fraction (LVEF) and 6 min walking distance (6MWD) of the study group were higher than those of the control group (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion:SGLT-2 inhibitors are effective in regulating and improving serological indexes abnormalities and cardiac function in patients with CHF combined with renal insufficiency.The clinical efficacy is definite and it is beneficial for improving prognosis of patient.
Chronic heart failureRenal insufficiencySodium-glucose cotransporter 2 inhibitorHeart function
万方数据
维普
